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RelA/p65 promotes osteoclast differentiation 
by blocking a RANKL-induced  
apoptotic JNK pathway in mice
Sergio Vaira,1 Muhammad Alhawagri,1 Imani Anwisye,1 Hideki Kitaura,2  
Roberta Faccio,2 and Deborah Veis Novack1,3
1Division of Bone and Mineral Diseases, Department of Medicine, 2Department of Orthopedic Surgery, and  
3Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA.
Osteoclasts	(OCs)	function	to	reabsorb	bone	and	are	responsible	for	the	bone	loss	associated	with	inflamma-
tory	arthritis	and	osteoporosis.	OC	numbers	are	elevated	in	most	disorders	of	accelerated	bone	destruction,	
reflecting	altered	rates	of	precursor	differentiation	and	apoptosis.	Both	of	these	processes	are	regulated	by	the	
JNK	family	of	MAP	kinases.	In	this	study,	we	have	demonstrated	that	the	NF-κB	subunit	RelA/p65	inhibits	JNK-
mediated	apoptosis	during	a	critical	period	of	commitment	to	the	OC	phenotype	in	response	to	the	cytokine	
RANKL.	This	RelA/p65-mediated	arrest	of	cell	death	led	to	enhanced	OC	differentiation.	Hence,	Rela–/–	
OC	precursors	displayed	prolonged	JNK	activation	in	response	to	RANKL,	and	this	was	accompanied	by	an	
increase	in	cell	death	that	prevented	efficient	differentiation.	Although	complete	blockade	of	JNK	activity	
inhibits	osteoclastogenesis,	both	short-term	blockade	in	RelA-deficient	cultures	and	suppression	of	the	down-
stream	mediator,	Bid	rescued	apoptosis	and	differentiation.	These	antiapoptotic	effects	were	RelA	specific,	
as	overexpression	of	RelA,	but	not	RelB,	blocked	apoptosis	and	rescued	differentiation	in	Rela–/–	precursors.	
Thus,	RelA	blocks	a	RANKL-induced,	apoptotic	JNK-Bid	pathway,	thereby	promoting	OC	differentiation.	
Consistent	with	this,	mice	lacking	RelA/p65	in	the	hematopoietic	compartment	were	shown	to	have	a	deficient	
osteoclastogenic	response	to	RANKL	and	were	protected	from	arthritis-induced	osteolysis.
Introduction
Osteoclasts (OCs) are multinucleated cells derived from myeloid 
bone marrow progenitors that express RANK, the receptor for the 
key osteoclastogenic cytokine RANKL (1). Increased OC formation 
and activity is observed in many osteopenic disorders, including 
postmenopausal osteoporosis, lytic bone metastasis, and rheuma-
toid arthritis, and leads to pain and structural instability. Osteoblast 
lineage cells express a membrane-bound form of RANKL, a member 
of the TNF cytokine family. Like other members of the TNF recep-
tor superfamily, RANK strongly activates the NF-κB pathway.
In mammals, the NF-κB family has 5 members: RelA/p65, RelB, 
c-Rel, NF-κB1/p50, and NF-κB2/p52 (2). In the canonical NF-κB 
pathway, ligation of RANK activates the inhibitor of IκB kinase 
(IKK) complex, which phosphorylates NF-κB–associated IκBα, 
leading to its ubiquitination and proteosomal degradation. These 
events release NF-κB dimers containing RelA and c-Rel in the 
cytosol, allowing them to translocate into the nucleus where they 
enhance transcription of target genes. In the alternative NF-κB 
pathway, NF-κB–inducing kinase (NIK) and IKKα target p100 for 
ubiquitination and processing, thereby allowing nuclear transloca-
tion of predominantly RelB-containing dimers.
The importance of NF-κB in osteoclastogenesis has been high-
lighted by several mouse models. Mice lacking both NF-κB1 and 
NF-κB2 have severe osteopetrosis with complete absence of OCs 
(3, 4). Ablation of IKKβ, a key component of the IKK complex, 
blocks nuclear translocation of RelA, RelB, and c-Rel and leads to 
increased bone mass and OC lineage apoptosis (5). Transduction 
of OC precursors with a superrepressor of IκBα that cannot be pro-
teasomally degraded blocks OC differentiation and survival (6, 7). 
Additionally, we have previously shown that ablation of NIK inhib-
its both RelA and RelB nuclear translocation in pre-OCs, leading 
to a resistance to RANKL-induced osteoclastogenesis in vivo and 
in vitro (8). Consistent with this observation, osteoclastogenesis 
and hence bone erosion are reduced in the serum transfer model of 
inflammatory arthritis in Nik–/– mice (9). These data suggest that 
tight regulation of the classical and alternative pathways is critical 
to the OC in both physiological and pathological circumstances. 
However, none of the previous studies have addressed the role of 
individual subunits in the OC response to RANKL.
Ablation of RelA in mice causes embryonic lethality, with exten-
sive liver apoptosis at E15.5 (10), dependent on TNF-α. Thus, defi-
ciency of either p55 TNF receptor (TNFR1) or TNF-α rescues this 
hepatic event and allows the doubly mutant mice to live at least 
to postnatal day 14–21 (11, 12). Ablation of TNFR1 in the IKKβ 
mutant mice also restored OC numbers in vivo, suggesting that 
TNF is the main driver of apoptosis in this lineage as well (5). One 
report has suggested that RANKL also induces OC lineage apop-
tosis, despite the lack of a death domain in its receptor RANK (13), 
although the mechanism has not been extensively explored.
Using genetic knockout approaches, the specific role of RelA has 
previously been examined in lymphocytes, lymph node stroma, 
hepatocytes, and neurons. Although several groups have demon-
strated potent RelA activation in OCs in response to RANKL and/or 
TNF, no studies have specifically addressed the unique role of this 
subunit. We have now used Rela–/–Tnfr1–/– mice to explore the role 
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of RelA in the OC lineage and find that this subunit plays a critical 
role in opposing cell death induced by RANKL during OC differ-
entiation. This apoptotic pathway is mediated by JNK and cannot 
be blocked by activation of RelB.
Results
Rela is important for RANKL-stimulated osteoclastogenesis in vivo. 
Although RelA-deficiency does not cause embryonic lethality 
on the Tnfr1–/– background, the double-knockout mice live an 
average of only 2–3 weeks. In order to analyze the subunit-spe-
cific role of RelA in the OCs of adult mice, we generated radia-
tion chimeras (RCs), engrafting C57BL/6J mice with bone mar-
row cells from Rela–/–Tnfr1–/– donors or Rela+/+Tnfr1–/– controls. 
Hematopoietic cells in the RCs are all Tnfr1–/– regardless of Rela 
genotype, and we will subsequently refer to these RCs as either 
Rela+/+ or Rela–/–. We performed histomorphometric analysis on 
vertebrae from RCs 4 months after engraftment and found a 
50% decrease in OC number and surface in Rela–/– relative to WT 
(Figure 1, A and B). There was no difference in trabecular bone 
volume (BV/TV) in Rela+/+ and Rela–/– chimeras. However, others 
have failed to detect differences in BV/TV in RCs bearing mar-
row with strong OC phenotypes such as RANK–/– (J. Lorenzo, 
personal communication).
The key cytokine required for OC differentiation from mono-
cyte lineage precursors is RANKL. To examine the osteoclastogenic 
response to RANKL more directly, we injected RANKL (100 μg/d, 
for 5 days subcutaneously) into Rela+/+ and Rela–/– RCs. Examina-
tion of tartrate resistant acid phosphatase–stained (TRAP) cal-
varia sections showed that the Rela+/+ controls had an increased 
OC number along calvarial sinuses and sutures compared with the 
PBS-injected controls (Figure 1, C and D). In contrast, Rela–/– RCs 
exhibited a blunted response to RANKL, indicated by fewer TRAP+ 
OCs on histomorphometric analysis and a significantly smaller 
rise in serum TRAP5b levels (Figure 1E). Thus, RelA is important 
for RANKL-stimulated osteoclastogenesis in vivo.
Absence of RelA protects mice from arthritis-induced bone loss but not 
inflammation. Blockade of NF-κB reduces both inflammation and 
bone loss in several murine models of inflammatory arthritis (9, 
14, 15). The Rela+/+ and Rela–/– RCs were injected with K/BxN serum 
(16) on days 0, 2, and 7, with LPS on day 2, to induce serum transfer 
arthritis. Histological sections of hind paws harvested at day 14 were 
stained with H&E and TRAP. H&E sections from Rela+/+ and Rela–/– 
RCs exhibited the same rate of infiltrate in the joint space, com-
posed primarily of neutrophils (Figure 2A), and the thickness of the 
hind paws of Rela–/– RCs was very similar to those of Rela+/+ controls 
through day 14 (Figure 2B), indicating that RelA is not important for 
the inflammatory response in this model. Another common feature 
of serum transfer arthritis is erosion of bones in the hind paw, with 
a large induction of osteoclastogenesis. Hind paws from Rela–/– RCs 
had fewer OCs compared with Rela+/+ RCs, both on the bone surface 
and in adjacent marrow, with 4-fold fewer OCs on the external bone 
surfaces (Figure 2, C and D). These results correlated with blunted 
induction of the serum marker collagen C-terminal telopeptide 
(CTX) at day 14 in Rela–/– RCs relative to Rela+/+ (Figure 2E). These 
results suggest that the RelA subunit is required for the osteoclasto-
genic response to inflammation.
RelA is important for OC precursor survival but not differentiation. 
To better understand the mechanism by which RelA impacts the 
OC, we turned to in vitro culture. In the presence of M-CSF and 
RANKL or in coculture with wild-type osteoblasts, bone marrow 
macrophages (BMMs) from RelA-deficient mice formed fewer OCs 
(Figure 3, A and B). The effect is dependent on the loss of RelA 
and not TNFR1, since reexpression of the latter did not rescue the 
phenotype (data not shown). During culture, we noticed fewer 
cells in RelA-deficient wells treated with RANKL and M-CSF, but 
Figure 1
RelA is important for basal and stimulated OC formation in vivo. (A) 
TRAP-stained sections of vertebrae from Rela+/+ and Rela–/– RCs 
4 months after bone marrow reconstitution. Scale bar: 100 μm. (B) 
Histomorphometric analysis was performed on TRAP-stained sections 
to determine the OC number (N.Oc./mm) and OC surface (Oc.S./BS.). 
*P < 0.05; n = 8/group. (C) Rela+/+ and Rela–/– RCs were injected with 
100-μg RANKL or PBS daily for 5 days and sacrificed on the sixth 
day. TRAP-stained coronal sections of calvaria at the sagittal suture 
show a consistent increase in OCs along sutures and sinusoids only 
in Rela+/+ RANKL-treated animals. Scale bar: 200 μm. (D) Quantifi-
cation of the N.Oc./mm and Oc.S./BS. (percentage of bone surface 
covered by OCs) along calvarial surfaces of mice in C confirms the 
significant difference in response of Rela+/+ and Rela–/– RCs to RANKL 
injection. In the PBS-injected animals, only rare OCs are detected in 
either genotype. †P < 0.005; n = 5/group. (E) Serum levels of TRAP5b 
were determined 1 day prior to first RANKL injection (baseline) and at 
sacrifice on day 6 (RANKL). ‡P = 0.01; n = 5/group.
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not in RelA-deficient wells treated with M-CSF alone. MTT assays 
(3-4, 5-dimethylthiazol-2y-2,5 diphenyltetrazolium bromide assays) 
confirmed a decreased cell number in Rela–/– cultures by 48 hours 
of RANKL treatment (Figure 3C), although there was no differ-
ence between Rela+/+ and Rela–/– cells cultured in M-CSF alone (data 
not shown). These data suggested that RelA plays an antiapop-
totic role. Therefore, we examined various markers of apoptosis in 
RANKL-stimulated cultures. In concordance with the MTT assay 
showing that significant cell loss in Rela–/– cultures occurs between 
24 and 48 hours of RANKL treatment, a DNA fragmentation assay 
showed that Rela–/– cultures treated with RANKL for 36 hours, 
but not 18 hours, had 3- to 4-fold higher levels of DNA fragmenta-
tion than M-CSF treated controls (Figure 3D). Interestingly, Rela+/+ 
cultures also had significant levels of DNA fragmentation after 
36 hours of RANKL exposure, although the levels were much less 
than for similarly treated Rela–/–. This RANKL-mediated apopto-
sis, accentuated by the absence of RelA, was confirmed by exami-
nation of caspase-3. Using a fluorimetric assay (Figure 3E), we 
found that while caspase-3 activation increased modestly (2-fold) 
in Rela+/+ precursors between 36 and 48 hours of RANKL exposure, 
caspase-3 was activated up to 4-fold in similarly treated Rela–/– cells 
during the same period. Caspase-9 activation was also elevated in 
the absence of RelA, while caspase-8 levels were unaffected (data 
not shown). These data indicate that RelA protects OC precursors 
from RANKL-induced cell death by blocking an intrinsic (caspase-
3/9 dependent) apoptotic pathway during a critical period of dif-
ferentiation (36–48 hours of RANKL exposure).
In order to determine if the failure to generate OCs was second-
ary to apoptosis and not due to a primary RelA effect on differ-
entiation, we used the caspase inhibitor ZVAD, in conjunction 
with RANKL, during the first 48 hours of OC differentiation. 
This treatment blocked the RANKL-induced caspase-3 activation 
(Figure 3E) and normalized the number of OCs generated from 
Rela–/– precursors after 6 days of culture (Figure 3F). We also found 
that Rela–/– OCs generated in the presence of ZVAD were able to 
form resorptive pits on bone slices (Figure 3G). These results dem-
onstrate that RelA is important for OC precursor survival but not 
differentiation or function.
A JNK-Bid pathway causes RANKL-mediated apoptosis in the absence of 
RelA. NF-κB has been implicated in the control of many antiapop-
totic genes, including Bcl2, BclxL, and the inhibitor of apoptosis 
(IAP) family (Ciap1, -2, Xiap). We therefore performed real-time 
quantitative PCR analysis to examine expression levels of these 
potential RelA targets in OC precursors. Of this group, only xiap 
was induced by RANKL in a RelA-dependent manner (Figure 4A, 
left panel). XIAP binds to and inhibits caspase-3 (17), and, there-
fore, may represent an important antiapoptotic signal controlled 
by RelA in response to RANKL in OC precursors.
In the context of TNF-α–mediated apoptosis, absence of RelA 
potentiates JNK activation. One mechanism is decreased via 
expression of Gadd45β, an inhibitor of the JNK kinase MKK7 (18). 
Others have described reduced activity of the MKP family of JNK 
phosphatases (19). In OC precursors, RANKL-induced expression 
of both Gadd45b and Mkp5 in a RelA-dependent manner (Figure 
4A), suggesting that JNK activation might also be altered in Rela–/– 
OC precursors. Although RANKL-induced JNK activation was 
normal in Rela–/– BMMs (data not shown), Rela–/– pre-OCs (BMMs 
cultured for 2 days in M-CSF and RANKL) showed stronger phos-
phorylation of JNK following starvation and restimulation with 
RANKL for 15 minutes (Figure 4B) and increased JNK kinase activ-
ity (data not shown). To determine whether this enhanced JNK acti-
vation is related to apoptosis in pre-OCs, we treated Rela–/– cultures 
Figure 2
Rela–/– RCs are protected from arthritis-induced bone loss. (A) Arthritis was induced in Rela+/+ and Rela–/– RCs 5 weeks after marrow transplanta-
tion by injection of K/BxN serum at days 0, 2, and 7, with LPS on day 2. Histological sections of ankle joints at day 14 stained with H&E show an 
extensive and similar inflammatory infiltrate in the joint spaces. Scale bar: 500 μm. (B) The inflammatory response was also evaluated by measure-
ment of hind paw thickness (sum of both paws) during induction of arthritis. n = 8/group. The experiment was repeated twice, with similar results. 
(C) TRAP-stained sections of metatarsals demonstrate OCs both on the outer bone surface adjacent to inflammatory pannus (arrowheads) and 
in marrow spaces. Scale bar: 100 μm. (D) Histomorphometric analysis of N.Oc./mm and Oc.S./BS. on the outer bone surface demonstrate sig-
nificantly more OCs in Rela+/+ RCs compared with Rela–/– RCs. *P < 0.001; n = 8/group. (E) Serum CTX was measured at day 0 and 14 of serum 
transfer arthritis, and the fold change for each RC was plotted, demonstrating a significant rise only in the Rela+/+ group. †P < 0.05; n = 6/group.
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with the JNK inhibitor SP600125, along with RANKL for 36 hours. 
Inhibition of JNK reduced DNA fragmentation to wild-type levels 
(Figure 4C) and restored osteoclastogenesis in Rela–/– precursors 
(Figure 4D), suggesting that JNK is mechanistically involved in 
RANKL-induced apoptosis in RelA-deficient OC precursors.
Enhanced JNK activation appears to initiate apoptosis by activat-
ing Bid, a proapoptotic BH3-only member of Bcl-2 family, at least 
in response to TNF (20). While Bid was expressed in both Rela+/+ 
and Rela–/– BMM cultures, levels were not affected by RANKL 
treatment in either genotype (Figure 5A), and cleavage products 
were not detected. In order to determine whether Bid is respon-
sible for RANKL-induced apoptosis, we employed a retroviral 
siRNA approach, using 2 different sequences to knock down Bid 
expression in Rela–/– OC precursors. Levels of Bid in Rela–/– BMMs 
Figure 3
Rela–/– BMMs are sensitive to RANKL-induced cell death. (A) Rela+/+ or Rela–/– BMMs were cultured in M-CSF and RANKL or (B) cultured with 
wild-type calvarial osteoblasts in the presence of 1,25 vitamin D3, then fixed and TRAP stained. Scale bar: 500 μm. The number of OCs per field 
(mean ± SEM) is shown, demonstrating fewer OCs in the absence of RelA. (C) Cell number was assessed by MTT assay in BMMs cultured with 
M-CSF and RANKL for 3–48 hours, showing fewer cells after 48 hours in Rela–/– cultures relative to Rela+/+ (*P < 0.00001; n = 4). (D) Apoptosis 
was measured by DNA fragmentation assay after 18 or 36 hours in the presence of M-CSF, with (+) or without (–) RANKL. After 36 hours, 
Rela–/– BMMs cultured with M-CSF and RANKL, but not with M-CSF alone, had increased cell death. ^ P < 0.0001 compared with Rela+/+ without 
RANKL at 36 hours; †P < 0.00001 relative to Rela+/+ with RANKL at 36 hours. (E) Caspase-3 (casp 3) activation was measured in Rela+/+ and 
Rela–/– BMMs cultured in M-CSF/RANKL for 36 and 48 hours, with or without ZVAD, and fold induction relative to the same cells in M-CSF alone 
was plotted. #P < 0.05 relative to Rela+/+ 36 hours; ‡P < 0.01, §P < 0.00001 relative to Rela+/+ at 36 or 48 hours. (F) OCs were generated with or 
without ZVAD during the first 48 hours. Scale bar: 500 μm. (G) OCs were generated as in F on cortical bone slices. Resorption pits (brown) were 
stained with horseradish peroxidase-conjugated wheat germ agglutinin. Scale bar: 100 μm.
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transduced with retroviral siRNA hairpins were decreased 85% for 
siBid1 and 55% for siBid2 compared with those transduced with an 
irrelevant siRNA-targeting luciferase, siLuc (Figure 5B). Culture of 
the same set of BMMs in RANKL showed a reduction of apoptosis 
back to Rela+/+ levels (Figure 5C) and restored OC numbers after 6 
days of culture (Figure 5D). Furthermore, analysis of bone resorp-
tion by OCs derived from siBid-transduced BMMs demonstrated 
that the function of surviving OCs was intact (Figure 5, E and F). 
The degree of Bid knockdown correlated with rescue of apoptosis, 
differentiation, and function. Thus, RelA opposes a proapoptotic 
pathway mediated by JNK and Bid in OC precursors.
Protection from RANKL-induced apoptosis is specific for RelA and not 
RelB. Previous studies of the function of NF-κB in OCs, including 
our own study of NIK (8, 9), have not established unique roles for 
individual subunits. Therefore, we examined the effect of RelA on 
the κB DNA-binding activity of RelB, controlled by the alternative 
NF-κB pathway, and c-Rel, controlled by the classical NF-κB path-
way. In RANKL-stimulated BMMs, levels of RelB κB-binding activity 
are similar in the presence and absence of RelA (Figure 6A), indicat-
ing that activation of the alternative pathway is not affected in these 
mice. The κB DNA-binding activity of c-Rel is also unchanged in 
Rela–/– cultures compared with Rela+/+ cultures, suggesting that c-Rel 
does not perform the same function as RelA.
To further address whether the classical subunit RelA has a distinct 
function from the alternative NF-κB subunit RelB, we analyzed apop-
tosis in RelB-deficient cultures. In contrast to Rela–/– BMMs, Relb–/– 
BMMs did not undergo apoptosis when cultured for 48 hours in the 
presence of RANKL (Figure 6B). Next, we asked if the overexpression 
of RelB could rescue the apoptosis induced by RANKL in RelA-defi-
cient OC precursors by using retroviral vectors to transduce Rela–/– 
BMMs. Immunoblots confirmed retroviral-mediated expression of 
both subunits (Figure 6C). As expected, expression of RelA reduced 
Figure 4
The absence of RelA leads to enhanced JNK activation. (A) Pre-OCs (BMMs cultured for 2 days with M-CSF and RANKL) generated from 
Rela+/+ (black bars) and Rela–/– (gray bars) mice were then starved of serum and cytokines and restimulated with RANKL for the indicated times 
prior to RNA extraction and real-time quantitative PCR for xiap, Gadd45b, and Mkp5. Rela–/– pre-OCs show significantly less induction of xiap, 
Gadd45b and Mkp5. *P < 0.5, **P < 0.01 compared to Rela+/+ at the same time point. (B) Rela+/+ and Rela–/– pre-OCs were starved and restimu-
lated with RANKL for the indicated times, and total lysates were analyzed by immunoblot for pJNK, demonstrating enhanced JNK activation in 
Rela–/– cultures. A parallel blot with equal loading was used to assess total JNK protein. (C) Rela+/+ and Rela–/– BMMs were cultured in RANKL, 
with or without the JNK inhibitor SP600125 (1 μm), for 36 hours Apoptosis was then assessed by DNA fragmentation assay. RANKL-mediated 
apoptosis was abrogated by the JNK inhibitor in Rela–/– cells. The data are representative of 3 independent experiments. †P < 0.05 Rela–/– versus 
Rela+/+ or Rela–/– with SP600125. (D) Rela+/+ and Rela–/– BMMs were cultured in osteoclastogenic conditions for 8 days, with or without SP600125 
for the first 36 hours, showing rescue of differentiation with short-term JNK inhibition. Scale bar: 200 μm.
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apoptosis to Rela+/+ levels (Figure 6D) and fully restored osteoclasto-
genesis in Rela–/– cells (Figure 6E). In contrast, retroviral expression of 
RelB did not affect levels of apoptosis and did not rescue osteoclasto-
genesis in Rela–/– BMMs, despite the ability of this construct to rescue 
the RelB-deficient phenotype (21). Thus, we conclude that the sub-
unit RelA specifically protects OC precursors from RANKL-induced 
apoptosis, and RelB cannot compensate for its absence.
Discussion
Many studies have demonstrated that NF-κB is an important 
therapeutic target in inflammatory diseases, including arthritis. 
However, it is also clear that NF-κB is critical for many normal cel-
lular functions and that global inhibition over prolonged periods, 
such as would be required in the treatment of chronic diseases, is 
likely to cause unacceptable side effects. Therefore, determining 
more restricted NF-κB targets is an important goal. The NF-κB 
family has 5 members, and although each subunit has been geneti-
cally ablated in mice, few subunit-specific roles have been defined 
in the context of disease models. In this study, we have focused on 
the prototypical subunit RelA/p65 and have delineated its role in 
the OC in vivo and in vitro.
The key cytokine for OC differentiation is RANKL, a member 
of the TNF superfamily. Like TNF-α, RANKL potently activates 
the classical NF-κB pathway with rapid nuclear translocation and 
Figure 5
Knockdown of Bid rescues Rela–/– osteoclastogenesis. (A) Rela+/+ and Rela–/– BMMs were stimulated with RANKL at the indicated times, and total 
cell lysates were examined by immunoblot for expression of Bid. β-actin was used as loading control. (B) Rela–/– BMMs were transduced with 
retrovirus expressing 2 different siRNAs for Bid (siBid1 and siBid2) or luciferase (siLuc). Following puromycin selection, levels of Bid were exam-
ined by immunoblot, demonstrating reduction of Bid by the specific siRNAs. β-actin was used as loading control. (C) Rela+/+ and Rela–/– BMMs 
transduced with siLuc or siBid1 or -2 were cultured with RANKL for 36 hours and DNA fragmentation was measured. The data are representa-
tive of 3 independent experiments. *P < 0.05 versus Rela+/+ siLuc. (D) The same BMMs in C were cultured in osteoclastogenic conditions for 6 
days, then stained for TRAP, showing rescue of differentiation with knockdown of Bid. Scale bar: 200 μm. (E) BMMs cultured on cortical bone 
slices were stained with horseradish peroxidase-conjugated wheat germ agglutinin to demonstrate resorption. Scale bar: 200 μm. (F) Pits in E 
were quantified, showing that reduction in apoptosis correlates with differentiation and bone resorption. Black bars indicate Rela+/+; gray bars 
indicate Rela–/–; *P < 0.05 versus Rela+/+ siLuc.
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DNA binding of RelA-containing dimers. Blockade of this classical 
pathway, by mutation or inhibition of IKKβ or IκB-superrepres-
sors, prevents activation of RelA and blocks osteoclastogenesis (5, 
7, 14). It therefore appeared that RelA was an important media-
tor of OC differentiation. We found that although Rela–/– precur-
sors do not differentiate well in standard osteoclastogenic culture 
conditions, this effect is completely dependent on an increase in 
apoptosis. When cell death is blocked, differentiation proceeds 
and fully functional bone-resorbing OCs are generated. We there-
fore conclude that RelA is not specifically required for the OC dif-
ferentiation transcriptional program.
TNFR1 bears a death domain in its cytoplasmic tail and can cause 
apoptosis via caspase-8. The role of NF-κB in opposing this apoptot-
ic TNF pathway has been studied extensively in several systems, and 
transcriptional targets have been described. In the OC lineage, block-
ade of classical NF-κB leads to TNF-mediated apoptosis (5, 6). In con-
trast to TNFR1, RANK does not have 
a death domain, and therefore, lacks 
an obvious mechanism by which to 
induce apoptosis. Nevertheless, at 
least 1 study using the RAW cell line 
(13) has suggested that RANKL can 
induce apoptosis in OC precursors 
dependent on JNK but independent 
of classical NF-κB. We find that in 
primary marrow macrophages lack-
ing both RelA and TNFR1, RANKL is 
a potent inducer of apoptosis medi-
ated by JNK, Bid, and caspase-3. The 
effect is dependent on the loss of 
RelA and not TNFR1, since the phe-
notype is not changed by reexpres-
sion of TNFR1. Furthermore, Li et 
al. (22) recently examined the bone 
phenotype of TNFR1-deficient mice 
and found elevated bone formation, 
due to increased osteoblast activity, 
but no change in bone resorption or 
OC parameters. These data support 
our conclusion that RANKL alone 
is able to induce apoptosis in OC 
precursors in the absence RelA, inde-
pendent of TNF effects. Additionally, 
because TNF can cause apoptosis via 
TNFR1 in RelA-deficient cells (23), 
we would predict that the absence 
of TNFR1 would be more likely to 
reduce the apoptotic response (as 
occurs in hepatocytes), rather than 
potentiate it.
The mechanism by which JNK acti-
vation leads to cell death has only been 
studied in the context of TNF signal-
ing. Franzoso and colleagues (18, 24) 
have shown that RelA mediates tran-
scription of Gadd45β, an inhibitor 
of MKK7, the activating kinase for 
JNK. In their model, absence of RelA 
downregulates Gadd45β, leading to 
prolonged activation of MKK7 and 
JNK in response to TNF. This aberrantly activated JNK causes cleav-
age of the proapoptotic Bcl-2 family member Bid to an active jBid 
form, leading to its translocation to the mitochondria and activation 
of the caspase-3 pathway (25). We find that RANKL fails to upregu-
late Gadd45β, as well as MKP5, in the absence of RelA and that acti-
vation of JNK is enhanced. Short-term blockade of JNK activation 
prevents RANKL-induced apoptosis in OC precursors, allowing their 
differentiation, as does reduction of Bid levels by siRNA. However, 
we are unable to detect the appearance of cleaved forms of Bid in 
our Rela–/– OC precursors, suggesting that there may be some differ-
ences in the pathways due to the cell lineage or the receptor initiating 
the pathway. In the context of anoikis (cell death induced by lack of 
adhesion), Bid can be activated without cleavage (26).
In the TNF pathway, ROS have been identified as the key media-
tor of the crosstalk between the NF-κB and JNK (27). In situations 
of impaired NF-κB signaling, generation of ROS is required for 
Figure 6
Enhanced RANKL-induced apoptosis is specific for RelA. (A) BMMs from Rela+/+ and Rela–/– mice were 
cultured in the presence of M-CSF and RANKL for 0 or 24 hours. Equal amounts of nuclear extracts 
were incubated with biotinylated κB oligos bound to streptavidin-coated beads. Beads were washed 
to isolate κB-bound proteins, and these were analyzed by immunoblot for RelB or c-Rel. Unbound 
nuclear proteins were analyzed by immunoblot for Sp1 as loading control. (B) BMMs from Relb+/+ and 
Relb–/– mice were cultured with M-CSF and RANKL for 48 hours, and apoptosis was assessed by DNA 
fragmentation assay, showing no effect of RelB on apoptosis. (C) Rela–/– BMMs retrovirally transduced 
with empty vector (EV), RelA, or RelB, and Rela+/+ BMMs transduced with EV were selected in blasto-
cydin, then analyzed by immunoblot. Viral-encoded proteins (both RelA and RelB), migrate more slowly 
than their endogenous (endo) counterparts, and are expressed at 2- to 3-fold over endogenous levels. 
(D) BMMs transduced in C were cultured with RANKL for 48 hours, and apoptosis was assessed by 
DNA fragmentation assay. While the EV control and RelB vectors do not abrogate the RANKL-induced 
cell death in Rela–/– cultures, RelA reduces apoptosis to the same level as Rela+/+ transduced with EV. 
*P < 0.001 Rela+/+ EV. (E) Transduced BMMs were grown in osteoclastogenic conditions for 6 days 
and then were fixed and stained for TRAP. Reexpression of RelA restores Rela–/– OC differentiation, 
while overexpression of RelB has no effect. Scale bar: 200 μm.
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TNF-mediated apoptosis. In the OC lineage, however, inhibition 
of ROS reduces differentiation and bone resorption (28, 29). JNK 
activation is also required for OC differentiation (30–32). RANKL 
activates both ROS and JNK, and these linked pathways contribute 
both differentiation and apoptotic signals. In the presence of RelA, 
apoptosis is suppressed and generation of OCs is optimal, while 
in the absence of RelA, precursor apoptosis reduces the number 
of mature bone-resorbing cells. Thus, there is a tight range of JNK 
activation required for osteoclastogenesis, and RelA is a critical 
component in maintaining appropriate levels. Furthermore, inhi-
bition of caspases or JNK within the first 2 days of RANKL culture 
restores differentiation in Rela–/– OC precursors, suggesting that 
timing of JNK activation might be as important as the magnitude.
Karin and coauthors (33) showed that TNF-α–mediated JNK 
activation induces apoptosis by accelerating turnover of the NF-κB 
regulated protein c-FLIP, an inhibitor of caspase-8, by upregulat-
ing the E3 ubiquitin ligase Itch. However, in Rela–/– OC precursors 
RANKL does not induce caspase-8 activation, so it is unlikely that 
c-FLIP and Itch are important mediators in response to RANKL.
RelA and RelB appear to have distinct functions in the OC lin-
eage. In the absence of RelA, OC precursors readily undergo apop-
tosis in response to RANKL but are capable of full differentiation 
and function if cell death is blocked. In contrast, RelB-deficient 
precursors are not susceptible to RANKL-mediated apoptosis but 
have a defect in differentiation (21). Absence of RelA does not affect 
signaling by RelB, and overexpression of the latter does not rescue 
the apoptotic Rela–/– phenotype. Another major difference between 
RelA and RelB is the kinetics of their activation by RANKL. RelA is 
activated within minutes of exposure of BMMs to RANKL and is 
relatively transient, while RelB activation takes hours and persists 
for days (D.V. Novack, unpublished observations). Whether the 
differences in RelA and RelB function lie in their upstream control 
mechanisms (IKKβ and NIK, respectively) or in the structure of the 
subunits themselves remains to be determined.
Previous studies have shown that inhibition of the classical 
NF-κB pathway blocks both inflammation and bone erosion in 
several models of inflammatory arthritis. We have now used radia-
tion chimeras bearing bone marrow from Rela–/–Tnfr1–/– mice 
or from Rela+/+Tnfr1–/– controls in the serum transfer model of 
arthritis. Despite the fact that hematopoietic cells in these RCs are 
unable to respond directly to TNF, inflammation develops with 
or without RelA. However, the presence of RelA was critical for 
the OC response. The number of OCs adjacent to inflammatory 
pannus on bone surfaces and their activity as measured by serum 
CTX levels were both markedly blunted in Rela–/– RCs. This effect 
is most likely mediated by RANKL, as opposed to other cytokines 
present during arthritis, since Rela–/– RCs also have a poor osteo-
clastogenic response to injection of exogenous RANKL.
In summary, we have demonstrated that despite the absence 
of a cytoplasmic death domain, RANK activates a proapoptotic 
pathway similar to that induced by TNFR1, with JNK, Bid, and 
caspase-3 playing key roles. The NF-κB subunit RelA has a cen-
tral, subunit-specific function in blocking this cell death to allow 
differentiation but is not required for the transcription of genes 
required for osteoclastogenesis.
Methods
Mice. Rela–/–Tnfr1–/– and relb–/– mice were maintained by heterozygote mat-
ings in a specific pathogen-free facility. The genotype of all mice used was 
confirmed by PCR analysis of genomic DNA extracted from tail biopsies. 
All experimental protocols were approved by the Institutional Animal 
Studies Committee at Washington University School of Medicine.
Bone marrow transplantation. Recipient 3- to 5-week-old C57BL/6J 
mice (The Jackson Laboratory) were administered 10 Gy total-body 
γ-irradiation 1 day prior to injection of 1 × 106 bone marrow cells from 
Rela+/+Tnfr1–/– or Rela–/–Tnfr1–/– donors via tail vein. The engraftment of 
transplanted marrow was confirmed by western blot for RelA (data not 
shown) on BMMs from the RCs.
Serum transfer arthritis. Arthritis was induced by intraperitoneal injection 
of 250 μl K/BxN serum at days 0, 2, and 7, with 50 μg LPS (E. coli 011; B4; 
Sigma-Aldrich) on day 2 as described (9). Ankle thickness in the hind paws 
was measured by dial gauge (Mitutoyo).
In vivo RANKL treatment. Rela+/+ and Rela–/– RCs were injected subcutane-
ously with GST-RANKL (500 μg per day for 5 days) or PBS (sham).
Measurement of serum TRAP5b and CTX. Immediately prior to sacrifice, 
mice were anesthetized and bled retro-orbitally. After clotting and centrifu-
gation, serum was collected and stored at –80°C prior to analysis using 
Mouse TRAP assay (IDS Inc.) or CTX (Rat Lap Elisa; Nordic Bioscience 
Diagnostic) according to the manufacturer’s instructions.
Bone histomorphometry. Mouse lumbar vertebrae, calvariae, or ankle joints 
were fixed overnight in formalin and decalcified in 14% EDTA. Paraffin-
embedded sections were stained with H&E or for TRAP activity. Bone sec-
tions were coded prior to analysis. Trabecular bone volume (BV/TV), OC 
surface (Oc.S/BS.), and OC numbers (N.Oc./B.Pm.) were measured by an 
observer blinded to genotype according to a standard protocol using Bio-
quant Osteo (Bioquant Image Analysis Corporation).
OC culture. BMMs were obtained and differentiated into OCs as described 
(34), using CMG14-12 as a source of M-CSF and recombinant GST-
RANKL. For osteoclastogenesis in 96-well plates, BMMs from Rela–/– and 
Rela+/+ mice were plated at 5 × 103 and cultured with 30 ng/ml of M-CSF 
(1:50 CMG supernatant). After 5 to 6 days the wells were fixed with 4% 
paraformaldehyde and OCs were visualized by histochemical staining for 
TRAP activity according to manufacturer’s instructions (Sigma-Aldrich). 
For coculture experiments, calvarial OCs and BMMs from Rela–/– and Rela+/+ 
mice were mixed at a ratio of 1:2 and cultured for 7 days in the presence of 
1,25 vitamin D3 (10–8 M) (Sigma-Aldrich).
Bone pit staining. BMMs were differentiated on bovine cortical bone slices 
with RANKL for 7–8 days. The staining of resorption lacuna was performed 
as described previously (35). Briefly, the cells were removed from the bone 
slices by wiping the surface of the bone slices with a soft brush, then slices 
were rinsed, incubated with 20 μg/ml peroxidase-conjugated wheat germ 
agglutinin (Sigma-Aldrich) for 30 minutes, and developed with 3, 3′-diami-
nobenzidine for 15 minutes.
MTT assay. BMMs were cultured in M-CSF, with or without GST-RANKL, 
for 3 to 48 hours, and the number of viable cells was measured by adding 10 μl 
MTT 5 mg/ml (3-4, 5-dimethylthiazol-2y-2,5 diphenyltetrazolium bro-
mide; Sigma-Aldrich) to 200 μl culture medium in each well and incubated 
at 37°C for 4 hours. To stop the reaction, 150 μl 0.04 N HCl in isopropanol 
was added to each well, and absorbance was determined at 570 nm.
DNA fragmentation assay. Cell death detection assay was performed with the 
Cell Death Detection Elisa kit (Roche Diagnostics Corp.) according to man-
ufacturer’s instructions. Rela+/+ and Rela–/– BMMs were cultured in 96-well 
plates for 36–48 hours in the presence of M-CSF (1:50 CMG supernatant) 
and GST-RANKL (150 ng/ml), with or without 10 μM ZVAD-FMK (R&D 
Systems) or the JNK inhibitor, SP600125 (1.0 μM) (Calbiochem) prior to 
lysis. Absorbance was read at 405 nm using Bio-Rad Microplate Reader.
Caspase activation fluorometric assays. The activation of caspase-3, -8, or 
-9 was measured according to the protocol of their respective fluoromet-
ric kits (Biovision). Cells in suspension were collected by centrifugation 
and mixed with adherent cells for lysis. Substrates were DEVD-AFC (cas-
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pase-3), FLICE (caspase-8), and LEHD-AFC (caspase-9). Fluorescence 
was read using Spectra Fluor (Tecan) with 400-nm excitation filter and 
505-nm emission filter.
Retroviral transduction. Retrovirus was generated by cloning murine relA 
(with an N-terminal HA tag) or relB cDNAs into the pMX-IRES-bsr vector 
adapted for the Gateway cloning system (Invitrogen) and transfected into 
platE packaging cells, using Transfectol (Gene Choice). Replication incom-
petent viral supernatant was added to BMMs for 24 hours, along with 
4 μg/ml polybrene (Sigma-Aldrich), prior to selection with blastocydin 
(1 μg/ml) for 3 days. Surviving, transduced BMMs were then cultured in 
a similar fashion to primary, unmanipulated BMMs. siRNAs for Bid were 
designed using the Dharmacon website (http://www.dharmacon.com/
DesignCenter) and cloned as a small hairpin into pSuper retroviral vector 
bearing the U6 promoter. SiBid1 sequence derived from the 3′ untranslat-
ed region is 5′-CAGCTTGAGTGTATCTGAA-3′; SiBid2 sequence derived 
from the open reading frame is 5′-GCTCTGGCTGTACTCGCCA-3′. PlatE 
packaging cells were transfected and BMMs were transduced as for the 
PMX vectors but with puromycin (2 μg/ml) selection, and the expression 
levels for BID were analyzed by western blot.
Immunoblotting analysis. Total protein was extracted as described (8). The 
proteins were quantitated with DC protein assay kit (Bio-Rad), and 40–50 μg 
of total protein were resolved by SDS-polyacrilamide gel electrophoresis 
under reducing conditions and then transferred to PVDF membrane. The 
blots were incubated for 1 hour in 5% dry milk and subsequently, overnight 
with the specific antibodies for pJNK, total JNK (Cell Signalling); RelA, 
RelB, c-Rel, SP1, β-actin (Santa Cruz Biotechnology Inc.); or Bid (R&D 
Systems); followed by anti-rabbit or anti-mouse HRP-conjugated second-
ary antibodies (Santa Cruz Biotechnology Inc.). Blots were evaluated by 
chemiluminescence using SuperSignal substrates (Pierce) and imaged with 
Genesnap, using the Syngene Imaging System (Synoptics). Relative protein 
expression was determined using Genetools (Synoptics).
κB pulldown assay. Nuclear extract (30 μg) was incubated with strep-
tavidin-coated agarose beads preincubated with biotinylated κB3 oligo-
nucleotide (8) for 30 minutes at 4°C on a rotator in 1x binding buffer 
(30 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, 5% glycerol, 1 mg/ml 
BSA, and 1 mM DTT) with 1 μg poly dIdC. Beads were then washed in 
1x binding buffer 3 times prior to SDS-PAGE and immunoblotted for 
RelB and/or c-Rel.
Real-time PCR. Total RNA was extracted using RNeasy (QIAGEN), and 
cDNA was generated with AMV-RT (Fisher) according to manufacturers’ 
instructions using 1 μg total RNA and oligo-dT primers diluted to a final 
volume of 100 μl. Quantitative RT-PCR was performed on an ABI7300 
Real-Time PCR system (Applied Biosystems) using SYBR Green PCR 
Master Mix assay (Applied Biosystems). The standard curve used a series 
of duplicate dilutions of plasmid for each gene and GAPDH cDNA. The 
amplification reaction was performed for 40 cycles with denaturation at 
95°C for 10 minutes, followed by annealing at 95°C for 15 seconds, and 
extension and detection at 60°C for 1 minutes. The relative RNA abun-
dance of each target gene transcript was normalized against endogenous 
gene control and calculated as 2–Δct (target gene – endogenous control 
gene), where ct represents the threshold cycle for each transcript.
Primers are as follows: Gapdh, 5′-CTTCACCACCATGGAGAAGGC-3′ 
and 5′-GACGGACACATTGGGGGTAG-3′; Xiap, 5′-TGCAAGAGCTG-
GATTTTATGC-3′ and 5′-GGTCTTCACTTGGCTTCCAAT-3′; Gadd45b, 
5′-TACGAGGCGGCCAAACTGATGAAT-3′ and 5′-ACGACTGGAT-
CAGGGTGAAGTGAA-3′; Mkp5, 5′-GAGAAAGGCCTCTTCAACTACAA-
3′ and 5′-CCACACTGGTGAGCTTCCTC-3′.
Statistics. Data are presented as mean ± SEM. Statistical significance was 
determined by 2-tailed Student’s t test using SigmaPlot (SSPS). P values ≤ 0.05 
were considered significant.
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